So far in 2022, the Food and Drug Administration’s main review office has approved 16 new medicines. The agency has recently cleared between 45 to 50 treatments each year, so the second half of the year could be busy if historical trends hold.
Three of the most important approval decisions the FDA will make are for drugs it’s been vetting for many months, having delayed previously scheduled deadlines. The next quarter will finally bring a verdict on two gene therapies and a closely watched ALS medicine.
